A Phase II Study on the Safety and Efficacy of 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) Followed by Paclitaxel in the Adjuvant Treatment of Breast Cancer

References

• Ferlay, J.; Bray, I.; Pisani, P.; Parkin, D M.; Globocan 2000. Cancer Incidence, Mortality and Prevalence Worldwide; IARC Press: Lyon, 2001.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352 (9132), 930–942.
   PubMed Web of Science ®Google Scholar
• French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 1988, 6 (4), 679–688.
   PubMed Web of Science ®Google Scholar
• Gluck, S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002, 9 (Suppl. 2), 16–27. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Davidson, N E. Ongoing US cooperative group trials using taxanes in the adjuvant setting. Clin. Breast Cancer 2002, 3 (Suppl. 2), S53–S58. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Thuerlimann, B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast Cancer 2001, 8 (4), 294–297., [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Holmes, F A.; Walters, R S.; Theriault, R L.; Forman, A D.; Newton, L K.; Raber, M N.; Buzdar, A U.; Frye, D K.; Hortobagyi, G N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 1991, 83 (24), 1797–1805. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Henderson, I C.; Berry, D A.; Demetri, G D.; Cirrincione, C T.; Goldstein, L J.; Martino, S.; Ingle, J N.; Cooper, M R.; Hayes, D F.; Tkaczuk, K H.; Fleming, G.; Holland, J F.; Duggan, D B.; Carpenter, J T.; Frei, E., III; Schilsky, R L.; Wood, W C.; Muss, H B.; Norton, L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003, 21 (6), 976–983. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Piccart, M J.; Lohrisch, C.; Duchateau, L.; Buyse, M. Taxanes in the adjuvant treatment of breast cancer: why not yet?. J. Natl. Cancer Inst. Monographs 2001, 30, 88–95. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Mamounas, E P.; Bryant, J.; Lembersky, B C.; Fisher, B.; Atkins, J N.; Fehrenbacher, L.; Raich, P C.; Yothers, G.; Soran, A.; Wolmark, N. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. Am. Soc. Clin. Oncol. 2003, 22, 4 Abstr. 12.
   PubMed Web of Science ®Google Scholar
• Buzdar, A U.; Singletary, S E.; Valero, V.; Booser, D J.; Ibrahim, N K.; Rahman, Z.; Theriault, R L.; Walters, R.; Rivera, E.; Smith, T L.; Holmes, F A.; Hoy, E.; Frye, D K.; Manuel, N.; Kau, S W.; McNeese, M D.; Strom, E.; Thomas, E.; Hunt, K.; Ames, F.; Berry, D.; Hortobagyi, G N. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 2002, 8 (5), 1073–1079. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ormrod, D.; Holm, K.; Goa, K.; Spencer, C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 1999, 15 (5), 389–416. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gehl, J.; Boesgaard, M.; Paaske, T.; Vittrup, J B.; Dombernowsky, P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol. 1996, 7 (7), 687–693. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gianni, L.; Munzone, E.; Capri, G.; Fulfaro, F.; Tarenzi, E.; Villani, F.; Spreafico, C.; Laffranchi, A.; Caraceni, A.; Martini, C. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 1995, 13 (11), 2688–2699. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gianni, L.; Vigano, L.; Locatelli, A.; Capri, G.; Giani, A.; Tarenzi, E.; Bonadonna, G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 1997, 15 (5), 1906–1915. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Valero, V.; Perez, E.; Dieras, V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin. Oncol. 2001, 28 (4 Suppl. 12), 15–23. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gennari, A.; Salvadori, B.; Donati, S.; Bengala, C.; Orlandini, C.; Danesi, R.; Del Tacca, M.; Bruzzi, P.; Conte, P F. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J. Clin. Oncol. 1999, 17 (11), 3596–3602. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rischin, D.; Smith, J.; Millward, M.; Lewis, C.; Boyer, M.; Richardson, G.; Toner, G.; Gurney, H.; McKendrick, J A. Phase II trial of paclitaxel and epirubicin in advanced breast cancer. Br. J. Cancer 2000, 83 (4), 438–442. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fisher, B.; Brown, A M.; Dimitrov, N V.; Poisson, R.; Redmond, C.; Margolese, R G.; Bowman, D.; Wolmark, N.; Wickerham, D L.; Kardinal, C G. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15. J. Clin. Oncol. 1990, 8 (9), 1483–1496. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial. J. Clin. Oncol. 2001, 19 (3), 602–611.
   PubMed Web of Science ®Google Scholar
• Levine, M N.; Bramwell, V H.; Pritchard, K I.; Norris, B D.; Shepherd, L E.; Abu-Zahra, H.; Findlay, B.; Warr, D.; Bowman, D.; Myles, J.; Arnold, A.; Vandenberg, T.; MacKenzie, R.; Robert, J.; Ottaway, J.; Burnell, M.; Williams, C K.; Tu, D.; National Cancer Institute of Canada Clinical Trials Group Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol. 1998, 16 (8), 2651–2658. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar